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The National Marrow Donor Program and Center for International Blood and Marrow Transplant Research
provided guidelines for the use of anti-HLA antibodies and HLA-DPemismatched loci in unrelated donor
hematopoietic stem cell transplantation (HSCT). However, a deeper understanding of other potentially useful
biomarkers for predicting clinical outcomes in HLA-A, -B, -C, -DRB1, -DQB1, and -DQA1 (12/12)ematched
unrelated donor HSCT is needed to further improve clinical outcomes. We tested HLA genotyping for 123
pairs of patients and donors. Anti-HLA antibodies using the Luminex method was applied to 123, 117, and 106
serum samples collected before and 1 month and 3 months after transplantation. The presences of anti-HLA
antibodies at the 3 time points were 37.4% (46 of 123), 40.2% (47 of 117), and 22.6% (24 of 106). Mismatch of
HLA-DPB1 and/or DPA1 allele between patient-donor pairs was 83.6% (92 of 110). Patients with anti-HLA
antibodies had delayed platelet recovery. The presence of anti-HLA antibodies and their dynamic changes
after transplantation were associated with increased occurrence of grades II to IV acute and chronic graft-
versus-host disease (GVHD), higher treatment-related mortality, and reduced overall survival (OS) and
disease-free survival, especially in acute myeloid leukemia and myelodysplastic syndrome patients. Multi-
variate analysis showed that presence of anti-HLA antibodies before transplantation was a risk factor for
GVHD and OS. Furthermore, HLA-DP lociematched subgroup showed a trend towards a lower rate of acute
GVHD and a higher OS in the anti-HLA Abs-negative group. Our results suggest that dynamic changes of anti-
HLA antibodies independently predict for a negative outcome of HSCT, independent of HLA-DP loci mis-
matches. Routine monitoring for anti-HLA antibody dynamics should be conducted before and after HSCT.
 2016 American Society for Blood and Marrow Transplantation.INTRODUCTION identity that can affect the outcomes of allo-HSCT, anti-HLA
Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) is an effective treatment for patients with hemato-
logical malignancies [1]. Besides factors such as age, sex,
disease stage, conditioning regimen, and degree of HLAedgments on page 94.
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ty for Blood and Marrow Transplantation.antibodies, especially donor-speciﬁc anti-HLA antibodies
(DSHAs), have been shown to have a negative prognostic
impact on patients who undergo cord blood transplantation
[2], haploidentical stem cell transplantation [3], and HLA-
mismatched unrelated stem cell transplantation [4]. Pos-
sessing anti-HLA antibodies or DSHAs has a negative effect
on engraftment and contributes to a lower overall survival
(OS) rate and higher graft failure [5-7]. The National Marrow
Donor Program and the Center for International Blood and
Marrow Transplant Research provided guidelines in 2012 in
which anti-HLA antibody and HLA-DP loci typing should be
Table 1
Characteristics of Patients and Donors
Anti-HLA Abs-Negative (n ¼ 77) Anti-HLA Abs- Positive (n ¼ 46) P Value
Patient age, median (range), yr 24 (9-59) 34 (8-58) .033
Patient sex
Male 56 (72.7) 22 (47.8)
Female 21 (27.3) 24 (52.2) .006
Months from Dx to Tx, median (range) 5 (3-144) 6 (3-192) .266
Sex matching
Matched 47 (62.3) 27 (58.7)
Male to female 16 (20.8) 16 (34.8)
Female to male 13 (16.9) 3 (6.5) .100
ABO type matching
Matched 23 (29.9) 16 (34.8)
Mismatched 54 (70.1) 30 (65.2) .571
Disease
AML 30 (39.0) 25 (54.3)
ALL 27 (35.1) 10 (21.7)
CML 7 (9.1) 5 (10.9)
MDS 9 (11.7) 5 (10.9)
NHL 4 (5.2) 1 (2.2) .430
Disease stage
Standard risk 56 (72.7) 35 (76.1)
High risk 21 (27.3) 11 (23.9) .832
Conditioning regimen
BU þ CY 66 (85.7) 39 (84.8)
TBI þ CY 9 (11.7) 4 (8.7)
FB/FC 2 (2.6) 3 (6.5) .499
GVHD prophylaxis
CsA þ MTX þ MMF 73 (100) 42 (100)
Number of MNC, median (range),  108/kg 7.18 (2.5-21.74) 7.49 (3.77-15.1) .324
Number of CD34þ, median (range),  106/kg 4.02 (1.98-11.014) 4.85 (1.3-9.99) .915
Donor age, median (range), yr 29 (20-45) 31 (21-47) .853
Donor sex
Male 59 (76.6) 35 (76.1)
Female 18 (23.4) 29 (23.9) .946
HLA-DP*
DPA1-M, DPB1-M 13 (19.7) 5 (11.4)
DPA1-M, DPB1-MM 14 (21.2) 4 (9.1)
DPA1-MM, DPB1-M 4 (6.1) 1 (2.3)
DPA1-MM, DPB1-MM 35 (53.0) 34 (77.3) .081
Dx indicates diagnosis; Tx, transplantation; NHL, non-Hodgkin lymphoma; Bu, busulfan; Cy, cyclophosphamide; TBI, total body irradiation; FB/FC, ﬂudarabineþ
busulfan/ﬂudarabine þ cyclophosphamide; CsA, Cyclosporine A; MTX, methotrexate; MMF, mycophenolate mofetil; MNC, mononuclear cells.
Data presented are n (%), unless otherwise indicated.
* n ¼ 110 evaluable, 13 samples with quality problem can not get the results of HLA-DP loci.
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unrelated adult donor and cord blood graft selection [8].
HLA typing is generally performed for 5 HLA loci (HLA-A,
-B, -C, -DRB1, and -DQB1) as mismatches at HLA-DPB1 and
DPA1 do not have a major effect on outcomes. Some re-
searchers have demonstrated that matching for HLA-A, -B,
-C, DRB1, -DQB1, and -DPB1 alleles between an unrelated
donor and the patient presents lower risks of acute graft-
versus-host disease (aGVHD) and mortality after allo-HSCT
[9-13]. However, previous studies of the clinical signiﬁ-
cance of anti-HLA antibodies were based on HLA-A, -B, -C,
-DRB1, and -DQB1 loci match or mismatch between the pa-
tient and donor, neglecting the effect of HLA-DP loci on
outcomes. We have recently identiﬁed a higher risk of
treatment-related mortality (TRM) and overall survival (OS)
in patients with anti-HLA antibodies undergoing HSCT [14]
and graft rejection in patients with de novo donor-speciﬁc
antibodies undergoing renal transplantation [15]. This rai-
ses the concern that pre-existing anti-HLA antibodies before
and after allo-HSCT may affect clinical signiﬁcance. Mean-
while, it is unclear if pre-existing anti-HLA antibodies and
HLA-DPB1 mismatches would correlate with each other and
the interactions increase unfavorable risk on outcomes of
allo-HSCT. In this study, we make a direct comparison of the
risks associated with pre-existing anti-HLA antibodies andHLA-DPB1 mismatched transplantations in HLA-A, -B, -C,
-DRB1, -DQB1- and -DQA1 (12/12)ematched unrelated
donor HSCT for patients with hematologic malignancies.
MATERIALS AND METHODS
Patients
The 123 patients with hematologic malignancies received transplants
from HLA-A, -B, -C, -DRB1, -DQB1, and -DQA1 (12/12)ematched unrelated
donors from China Marrow Donor Program. Serum samples before the start
of conditioning treatment and 1 month and 3 months after transplantation
were included in the study. All patients gave written informed consent for
HSCT between October 2011 and March 2014 in the First Afﬁliated Hospital
of Soochow University and the study followed the ethical guidelines of the
Declaration of Helsinki. The last follow-up was on May 24, 2014 and the
median follow-up time was 10.7 months (range, .1 to 29.7 months).
Median patient age at transplantation was 27 years (range, 8 to
59 years). There were 78 males and 45 females in the cohort. All patients
underwent HLA 12/12ematched unrelated donor HSCT for acute myeloid
leukemia (AML, n ¼ 55), myelodysplastic syndrome (MDS, n ¼ 14), chronic
myelogenous leukemia (CML, n ¼ 12), acute lymphoblastic leukemia (ALL,
n ¼ 37), and non-Hodgkin lymphoma (n ¼ 5). Transplantation risk was
deﬁned as follows: AML, ALL, and non-Hodgkin lymphoma in ﬁrst complete
remission, CML in ﬁrst chronic phase, and MDS subtype refractory anemia
were considered to be standard risk; others were considered high risk.
Conditioning Regimen and Graft-versus-Host Disease Prophylaxis
All patients receivedmyeloablative conditioning. Most patients received
a conditioning regimen consisting of cytarabine at 2 g/m2 every 12 hours (on
days -9 and -8), busulfan at 1 mg/kg every 6 hours (on days -7 to -5), and
Table 2
Anti-HLA Antibodies Detected before and One Month and Three Months after Allo-HSCT
Pre-TX of Anti-HLA Ab Negative Group, n ¼ 77 (62.6%) Pre-Tx of Anti-HLA Ab Positive Group, n ¼ 46 (37.4%)
1 Month 3 Months Pre-Tx 1 Month 3 Months
n ¼ 75 MFI Abs n ¼ 66 MFI Abs MFI Abs n ¼ 42 MFI Abs n ¼ 40 MFI Abs
Neg, n ¼ 52 (69.3%) neg, n ¼ 47 (71.2%) SP ¼ 4,
IP ¼ 6,
P ¼ 6,
WP ¼ 2
I ¼ 4, II ¼ 4,
I & II ¼ 10
neg, n ¼ 18 (42.9%) neg, n ¼ 18 (45.0%)
pos, n ¼ 1 (1.6%) WP HLA-I
4* (NC ¼ 4)
Pos, n ¼ 23 (30.7%) SP ¼ 1, IP ¼ 1,
P ¼ 5, WP ¼ 2
I ¼ 4,
I & II ¼ 5
pos, n ¼ 9 (13.6%) IP ¼ 2,
P ¼ 3,
WP ¼ 4
I ¼ 6, I
& II ¼ 3
SP ¼ 6,
IP ¼ 4,
P ¼ 3,
WP ¼ 1
I ¼ 5, II ¼ 1,
I & II ¼ 8
pos, n ¼ 24 (57.1%) SP ¼ 4, IP ¼ 3,
P ¼ 5, WP ¼ 2
I ¼ 3, II ¼ 3,
I & II ¼ 8
pos, n ¼ 14 (35.0%) SP ¼ 2,
IP ¼ 3,
P ¼ 4,
WP ¼ 5
I ¼ 5,
II ¼ 5,
I & II ¼ 4
SP ¼ 1,
P ¼ 4, WP ¼ 4
I ¼ 6, II ¼ 2,
I & II ¼ 1
neg, n ¼ 9 (13.6%) IP ¼ 2,
P ¼ 3,
WP ¼ 3
I ¼ 5, II ¼ 1,
I & II ¼ 2
SP ¼ 0, IP ¼ 1,
P ¼ 4, WP ¼ 3
I ¼ 3, II ¼ 2,
I & II ¼ 3
neg, n ¼ 8 (20.0%)
SP ¼ 1,
P ¼ 1, WP ¼ 2
I ¼ 4, II ¼ 1 5* (D ¼ 2, NC ¼ 3) SP ¼ 1,
IP ¼ 1
I & II ¼ 2 SP ¼ 1, WP ¼ 1 I ¼ 1, I &
II ¼ 1
2* (D ¼ 1, NC ¼ 1)
2* (D ¼ 1, NC ¼ 1) SP ¼ 3,
P ¼ 1
I ¼ 3,
I & II ¼ 1
4* (D ¼ 2, NC ¼ 2)
P ¼ .03 P ¼ .044
pre-Tx, pre-transplantation; neg, negative; pos, positive; SP, strongly positive levels; IP, intermediately positive levels; P, positive levels; WP, weakly positive levels; I, anti-HLA class I antibodies positive; II, anti-HLA class II
antibodies positive; I & II, anti-HLA class I & II antibodies positive.
* No. of patients who died (D) or lost contact (NC).
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Figure 1. Anti-HLA positive antibodies and aGVHD. (A) The cumulative incidence of aGVHD and anti-HLA antibodies. (B) The cumulative incidence of aGVHD and MFI.
Z. Pan et al. / Biol Blood Marrow Transplant 22 (2016) 86e95 89cyclophosphamide at 50 mg/kg/day (on days -4 to -3). Patients with high-
risk central nervous system leukemia received a similar regimen but with
total body irradiation (12 Gy, lung shielding at 8 Gy separated by 3 days, on
days -7 to -5) substituted for busulfan and cytarabine. Graft-versus-host
disease (GVHD) prophylaxis consisted of continuous cyclosporine A infu-
sion at 3 mg/kg/day and mycophenolate mofetil oral formulation at 15 mg/
kg every 12 hours starting on day -9, short-term methotrexate given on
days þ1, þ3, þ6, and þ11 at doses of 15, 10, 10, and 10 mg/m2, respectively,
and antithymoglobulin was given on days -5 to -2 at 2.5 mg/kg/day.
HLA Genotyping
Genomic DNA was extracted from peripheral blood using a DNA
extraction kit (Promega, Madison, WI) according to the manufacturer’s
protocol. Allelic typing for HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 was
performed by both sequence-based typing using Allele SEQR kits (Atria,
South San Francisco, CA) and sequence-speciﬁc oligonucleotide probe
(SSOP) using LABType SSO kits (One Lambda, Los Angeles, CA). Allelic typing
for DPA1 and DQA1 were performed by SSOP method using LABType SSO
kits (One Lambda, Los Angeles, CA). Any ambiguities after sequence-based
typing and SSOP were resolved by high-resolution sequence-speciﬁc
primers using allele-speciﬁc HLA typing trays (Olerup, Stockholm, Sweden)
to get the 4-digit alleles.
ANTI-HLA ANTIBODY DETECTION
Serum samples collected before and after transplantation
were examined using HLA class I, II, and major histocom-
patibility complex class Ierelated chain A mixed antigen
beads (LABScreen beads, One Lambda, Canoga Park, CA)
according to manufacturer’s instructions. The anti-HLA
antibody reactivity was detected in a Luminex platform
(Luminex, Canoga Park, CA). Data were analyzed with the
LABScan 200 software (One Lambda). Samples with mean
ﬂuorescence intensity (MFI) of 500 or more when adjusted
for background were considered positive and were tested
with the LABScreen single-antigen bead assay (One Lambda).
Samples that were weakly positive during screening
(MFI < 500 but with the intensity of 1 or more beads
signiﬁcantly higher than the other beads) also underwent
LABScreen single-antigen bead assay. Internal proﬁciency
testing for anti-HLA antibody detection includes 1 American
Society for Histocompatibility and Immunogeneticsepositive
quality control sample and 1 negative control serums from
One Lambda.
The cut-off value of MFI for the mixed antigen bead assay
is 500. MFI < 500 was considered negative, 500 to 1000 was
considered weakly positive, 1000 to 2000 was considered
positive, 2000 to 5000 was considered intermediately posi-
tive, and>5000was considered strongly positive. The results
of single-antigen assay were compared with the HLA typing
of donors to determine whether the anti-HLA antibodies
detected were DSHAs.Deﬁnitions
Neutrophil recovery was deﬁned as the ﬁrst of 3 consec-
utive days with an absolute neutrophil count  .5  109/L
and platelet recovery was deﬁned as the ﬁrst day of 3
consecutive days with platelet counts higher than
20  109/L without transfusion support. The grades of acute
and chronic GVHD were assessed according to published
consensus criteria. OS was deﬁned as the time between
graft infusion and death from any cause. Disease-free sur-
vival (DFS) was calculated from the time of transplantation
to the time of relapse or death. TRMwas deﬁned as the time
to death from any cause but relapse. DHSAs were deemed as
the speciﬁcity of anti-HLA antibodies (the results of single-
antigen assays) corresponding to donor’s HLA-DPB1 mis-
matched antigens.Statistical Analysis
The categorical variables between the groups with and
without antibodies were compared using chi-square test
(Fisher’s exact test when required) and the continuous
variables were compared using nonparametric test (Mann-
Whitney test). OS and DFS were calculated using the Kaplan-
Meier method and compared using log-rank test. We
assessed the association of the various related variables
(anti-HLA antibodies, HLA-DP matching, patient’s and do-
nor’s age, patient’s and donor’s sex, ABO blood type, disease
stage, type of conditioning, infusion cell dose, and time from
diagnosis to transplantation) on OS and DFS using Cox
regression. We examined the association of the probability
of the binary outcome of aGVHD, chronic GVHD (cGVHD),
and TRM using logistic regression. The statistical software
SPSS 17.0 (SPSS Inc., Chicago, IL) was used and P values no
more than .05 were considered statistically signiﬁcant. Data
graphs were drawn in Graphpad Prism 5.0 (GraphPad Soft-
ware, Inc., San Diego, CA).RESULTS
Characteristics of the Transplantation Recipients and
Donors
A total of 110 (89.4%) of the HLA 12/12ematched
recipient-donor pairs were genotyped for HLA-DPA1 and
HLA-DPB1 (13 specimens with quality problems were
excluded from the analysis), 18 (16.4%, 18 of 110) recipient-
donor pairs were matched in 16/16 alleles at HLA-A, -B, -C,
-DRB1, -DQB1, -DQA1, -DPA1, and -DPB1, and 92 (83.6%, 92
of 110) recipients-donor pairs were mismatched in HLA-
DPA1 and/or HLA-DPB1 locus. Among them, 69 pairs were
Z. Pan et al. / Biol Blood Marrow Transplant 22 (2016) 86e9590mismatched at both DPB1 and DPA1 loci, 18 pairs were
mismatched at the HLA-DPB1 loci, and 5 pairs were mis-
matched at the HLA-DPA1 loci.
Forty-six patients (37.4%, 46 of 123) were found to have
anti-HLA antibodies before transplantation. Of the 46
antibody-positive cases, 18 (14.6%) patients had anti-HLA
class I antibodies, 6 (4.9%) patients had anti-HLA class II an-
tibodies, and 22 (17.9%) patients had anti-HLA class I and II
antibodies. Strongly positive antibody levels (MFI > 5000)
were found in 14 patients, whereas 13, 13, and 6 patients had
intermediately positive, positive, and weakly positive levels,
respectively. The speciﬁcity of anti-HLA DP antibodies was
examined in the context of DP loci mismatches in 92 donor-
patient pairs. And 6 (6.5%, 6 of 92) patients were found to
have DSHAs (anti-HLA-DPB1 antibodies) referring to the HLA
typing of the donor with DPB1 antigen.
The characteristics of the study population are shown in
Table 1. The proportion of females among pre-existing anti-
HLA Abs-positive patients was signiﬁcantly higher than
negative patients (52.2% versus 27.3%, P ¼ .006). Further-
more, female patients with a history of previous pregnancies
showed a higher prevalence of anti-HLA antibodies (70.8%
versus 38.1%, P ¼ .027). Patients with pre-existing anti-HLA
antibodies tended to be older (mean of 34 versus 24 years,
P ¼ .033). HLA-DP matching status, disease type, the months
from diagnosis to transplantation, conditioning regimen, and
number of stem cells were similar in anti-HLA Abs-positive
and Abs-negative pairs.
Dynamic Changes of anti-HLA Antibodies after
Transplantation
The total number of allo-HSCT recipients included in this
study at 1 and 3 months after transplantation was 117 and
106, respectively. Six patients died and 11 patients were lost
to follow-up during the 3 months after transplantation. In
the follow-up period after allo-HSCT, anti-HLA antibodies
gradually taper off. The presence of anti-HLA antibodies
before transplantation, and at 1 month and 3 months after
transplantation was 37.4% (46 of 123), 40.2% (47 of 117),
22.6% (24 of 106), respectively (P ¼ .013). The MFI level of
most patients with positive antibodies was also gradually
reduced.
In the anti-HLA Abs-negative group before trans-
plantation, the proportions of recipients at 1 and 3 month
after transplantation who had no anti-HLA antibodies were
69.3% and 84.8%, respectively, whereas those of the re-
cipients who turned positive were 30.7% and 15.2%, respec-
tively (P ¼ .03). In the anti-HLA Abs-positive group before
transplantation, the proportions of recipients who continu-
ously has anti-HLA antibodies were 57.1% and 35.0%, whereas
those of the recipients who converted to negative was 42.9%
and 65.0% at 1 month and 3 months after transplantation,
respectively (P¼ .044). Patients who had anti-HLA antibodies
before transplantation were more likely to have persistent
antibodies at 1 month (P ¼ .005) and 3 months (P ¼ .018)
after transplantation. The details of the type of change of
anti-HLA antibodies detected at different time-points after
transplantation are presented in Table 2.
Six patients who were DSHA positive before trans-
plantation were converted to negative at 1 month after
transplantation. Among them, 3 patients died from disease
relapse and 3 patients survived. In addition, we found 2
patients without antibodies before transplantation who had
de novo DSHAs after transplantation. One patient who sur-
vived had de novo DSHAs at 3 months after transplantationas follow: DP5 (MFI 666) and 1 patient who died from
multiple organ dysfunction syndrome at 2 months had de
novo DSHAs as follow: DP13 (MFI 668), DP14 (MFI 532).
Effect of anti-HLA Antibodies Detected before and after
Allo-HSCT, and Their Titers, on Hematologic Recovery,
GVHD, OS, DFS, Relapse, and Infection
Hematologic recovery
Three patients died before hematologic recovery. The
median time of neutrophil and platelet recovery in the pa-
tient with pretransplantation anti-HLA Abs-positive group
was 12 (range, 10 to 19) and 14 (range, 11 to 50) days, and in
the Abs-negative group they were 12 (range, 9 to 17) and 13
(range, 7 to 43) days, respectively. No signiﬁcant differences
in neutrophil engraftment were observed between the 2
groups (P¼ .877). However, there was a signiﬁcant difference
in the 2 groups in the recovery of platelets (P ¼ .033). Un-
fortunately, DSHAs had no effect on neutrophil recovery
(P ¼ .676) and platelet recovery (P ¼ .151).
aGVHD
The cumulative incidences of grades II to IV aGVHD for the
entire cohort was 28.7% within 100 days after trans-
plantation. Patients with anti-HLA antibodies had a higher
rate of grades II to IV aGVHD than those without antibodies
(43.3% versus 20.4%, P ¼ .0062, hazard ratio [HR], 2.783; 95%
conﬁdence interval [CI], 1.338 to 5.788) (Figure 1A). More-
over, when grade II aGVHD was excluded, there was a sig-
niﬁcant increase in the risk of grades III and IV aGVHD
recorded in the Abs-positive group compared with Abs-
negative group (22.1% versus 9.1%, P ¼ .0444). Furthermore,
the presence of anti-HLA antibodies with MFI of 500 to 1000
was associated with a higher incidence of grades II to IV
aGVHD compared with those positive for anti-HLA anti-
bodies but with MFI >1000 or negative for anti-HLA anti-
bodies (66.7% versus 39.5% versus 20.4%, P ¼ .0015)
(Figure 1B). The incidences of grades II to IV aGVHD were
31.3%, 45.5%, 50.0%, and 19.7%, respectively, in anti-HLA class
I antibodiesepositive group, class I and IIepositive group,
class IIepositive group, and antibodies-negative group.
Interestingly, the cumulative incidences of grades II to IV
aGVHD were 68.8%, 41.2%, and 20.4% respectively in the
DSHAs, non-DSHAs, and negative groups (P ¼ .0212). The
incidences of the grades II to IV aGVHD were no different in
DSHAs and non-DSHAs groups (P ¼ .6884). In univariate
analysis, female patients and months from diagnosis to
transplantation above the median showed trends of associ-
ation with higher incidence of aGVHD.
All patients with or without anti-HLA antibodies before
and 1 month after transplantation were divided into 4
groups: negative and negative (group i, n ¼ 52), negative to
positive (group ii, n ¼ 23), positive and positive (group iii,
n ¼ 24), positive to negative (group iv, n ¼ 18). The in-
cidences of grades II to IV aGVHD were 21.2%, 17.4%, 33.3%,
and 55.6%, respectively, in the 4 groups (P¼ .02, Table 3). The
incidences of grades II to IV aGVHD did not differ signiﬁ-
cantly between group i and group iii (P ¼ .25) but there was
signiﬁcant difference between group i and group iv (P ¼ .01).
According to the changes of anti-HLA antibodies before
and 1 month and 3 months after transplantation, all patients
were divided into 6 groups: negative and negative and
negative (group 1, n ¼ 47), negative to positive and positive
(group 2, n ¼ 9), negative to positive to negative (group 3,
n ¼ 9), positive and positive and positive (group 4, n ¼ 14),
positive and positive to negative (group 5, n ¼ 8), positive to
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Z. Pan et al. / Biol Blood Marrow Transplant 22 (2016) 86e95 91negative and negative (group 6, n ¼ 18). There was no sig-
niﬁcant difference in grades II to IV aGVHD between the 6
groups (P ¼ .14, Table 3) or between groups 2, 4, and 6
(P ¼ .08). In addition, the incidences of grades II to IV aGVHD
were signiﬁcantly different between groups 1, 2, 4, and 6
(P ¼ .05), which suggested that patients with antibodies
continuously negative had better outcomes.
cGVHD
Only patients alive on day 100 were included in the
cGVHD analysis (n ¼ 113). All patients were assigned to 2
groups according to the presence of anti-HLA antibody in the
recipients. A lower rate of cGVHD was observed in anti-HLA
Abs-negative group (32.4%), whereas the Abs-positive group
had a higher rate (52.4%, P¼ .036). The incidence of extensive
cGVHD was also signiﬁcantly different between the 2 groups
(9.9% versus 23.8%, P ¼ .045).
All patients were divided into 2 groups according to the
presence of anti-HLA antibodies detected during follow-up:
the continuously negative antibodies group (n ¼ 46) and
the positive group, including transiently or continuously
positive antibodies (n ¼ 65). The incidence of cGVHD in 2
groups was 32.6% and 43.1% (P ¼ .269). Among the
antibodies-positive group, the incidence of cGVHD in the
continuously positive group was 61.5%, antibodies from
positive to negative group was 38.9%, and antibodies from
negative to positive group was 44.4% (P¼ .508). Patients with
continuously positive antibodies had a trend of higher
cGVHD compared with patients with continuously negative
antibodies (P ¼ .061).
Relapse, TRM, and infection
A total of 19 patients (15.4%) relapsed by the time of the
last follow-up, with a median relapse time from HSCT of
4.6 months (range, 1.5 to 17 months). The cumulative inci-
dence of relapse was 17.1% at 12 months and 22.0% at
24 months after transplantation. The cumulative incidences
of relapse in the anti-HLA antibodiesenegative group
andepositive group were 17.5% and 29.8%, respectively
(P ¼ .1250).
There were 18 cases of TRM, which included infections
(n ¼ 7), GVHD (n ¼ 6), and other causes (n ¼ 5). The cu-
mulative incidences of TRM in the anti-HLA Abs-negative
group and Abs-positive group were 15.8% and 33.1%,
respectively (P ¼ .2239).
There was no signiﬁcant difference in cytomegalovirus
(43.2% versus 48.7%, P ¼ .560) and Epstein-Barr virus (27.4%
versus 27.3%, P ¼ .545) infection after transplantation be-
tween anti-HLA Abs-negative group and Abs-positive group.
OS and DFS
At the last follow-up, 90 patients were alive and 33 pa-
tients had died. The percentages of OS and DFS in 2 years
were 73.2% and 69.1%, respectively. The 2-year probabilities
of OS for AML/MDS, ALL, and CML patients were 56.4%, 65.7%,
and 88.9%, respectively (P ¼ .2757). The 2-year probabilities
of DFS for AML/MDS, ALL, and CML patients were 53.1%,
58.2%, and 88.9%, respectively (P ¼ .2167).
Patients with anti-HLA antibodies had a signiﬁcantly
lower 2-year OS than those without anti-HLA antibodies
(50.2% versus 65.7%; P ¼ .0293; HR, 2.202; 95% CI, 1.082 to
4.48) (Figure 2A). When only the 69 AML/MDS patients, who
had a higher positive rate of anti-HLA antibodies, were
considered, the effect of anti-HLA Abs-positive on OS was
apparent (35.3% versus 74.3%; P ¼ .0062; HR, 3.307; 95% CI,
Figure 2. Preformed anti-HLA positive antibodies and survival. (A) Preformed anti-HLA antibodies on OS for all patients. (B) Preformed anti-HLA antibodies and OS
for AML/MDS patients. (C) Preformed anti-HLA antibodies and DFS for all patients. (D) Preformed anti-HLA antibodies and DFS and AML/MDS patients.
Z. Pan et al. / Biol Blood Marrow Transplant 22 (2016) 86e95921.404 to 7.787) (Figure 2B). However, the effect on OSwas not
found in patients with ALL (59.9% versus 74.1%, P ¼ .5627) or
with CML (75.0% versus 100%, P ¼ .2636). In addition, a sig-
niﬁcant difference in OS was observed in patients with anti-
HLA antibodies positive and anti-HLA antibodies negative
(50.2 versus 65.7%, P ¼ .0513; HR, 2.831; 95% CI, .9942 to
8.059). Analysis of DFS showed no signiﬁcant difference,
although a trend towards worse survival was observed in the
anti-HLA antibodies positive group (46.6% versus 61.8%,
P ¼ .0820; HR, 1.8; 95% CI, .9282 to 3.490) (Figure 2C).
Moreover, DFS was reduced in the anti-HLA antibodies pos-
itive group in AML/MDS patients (36.3% versus 68.3%;
P ¼ .0254; HR, 2.546; 95% CI, 1.122 to 5.775) (Figure 2D).
There was no statistical signiﬁcance in OS difference (52.9%
versus 69.6% versus 50.0% versus 77.6%, P ¼ .12) and DFS
(52.9% versus 65.2% versus 50.0% versus 75.3%, P ¼ .162) in
anti-HLA class I antibodies positive group, class I & II positive
group, class II positive group, and antibodies negative group.
No association was identiﬁed between OS and DSHAs
(P ¼ .7637).
The dynamic changes of antibodies from before to after
transplantation inﬂuenced OS, DFS, and TRM. OS (84.6%
versus 73.9% versus 62.5% versus 61.1%, P ¼ .08) and DFS
(78.8% versus 69.6% versus 58.3% versus 61.1%, P ¼ .24) did
not differ signiﬁcantly among the 4 groups, but TRM (8.8%
versus 13.0% versus 33.3% versus 5.6%, P ¼ .03) showed a
signiﬁcant difference in the 4 groups, which results from the
change of antibodies detected before and 1 month after
transplantation (Table 3). Moreover, there were differences
in OS (P ¼ .03), DFS (P ¼ .06), and TRM (P ¼ .02) between
group i and group iii. The effects of changes of anti-HLA
antibodies on OS (P ¼ .26), DFS (P ¼ .51), and TRM (P ¼ .36)
were not signiﬁcantly different in the 6 groups (Table 3).
Even so, we found that OS and DFS of the continuouslynegative group were always better than those of the
continuously positive group.
Inﬂuence of HLA-DP Loci Mismatches on Outcomes after
HLA-matched (12/12) Unrelated Donor Allo-HSCT
One hundred ten recipient-donor pairs were assigned to 2
groups according to the HLA-DP lociematched or mis-
matched. No signiﬁcant differences in grades II to IV aGVHD
(24.6% versus 32.3%, P ¼ .6102), OS (43.2% versus 34.2%,
P ¼ .7776), and DFS (56.3% versus 46.2%, P ¼ .8731) were
observed in patients receiving grafts from either HLA-DP
lociematched donors or HLA-DP lociemismatched donors.
In addition, divisions of HLA-DP lociemismatched group into
HLA-DPA1 lociemismatched group, HLA-DPB1
lociemismatched group, and both lociemismatched group
were uniform and showed no differences in grades II to IV
aGVHD (P ¼ .3963), OS (P ¼ .9741), and DFS (P ¼ .9928).
Because of the lack of statistical signiﬁcance with HLA-
DPA1 and DPB1 mismatches, we merged HLA-DPA1 and
-DPB1eloci mismatches into HLA-DPeloci mismatches to
analyze their inﬂuence on outcomes after transplantation in
the subsequent statistics. The data from the comparison
between the HLA-DPB1 permissive mismatches group and
the nonpermissive mismatches group will be reported in
another paper.
Synergistic Impact of Preformed anti-HLA Abs and HLA-
DP Loci Mismatches on Outcomes
In the anti-HLA Abs-negative group, patients with HLA-
DP loci mismatches had a trend of delays in neutrophil re-
covery compared with patients matched at HLA-DP
(P ¼ .053). The prevalence of HLA-DP loci mismatches had
a minor effect on platelet recovery (data not shown). The
cumulative incidences of grades II to IV aGVHD in the
Figure 3. Anti-HLA antibodies with HLA-DP loci mismatches and outcomes.
(A) Anti-HLA antibody negative group, HLA-DP loci mismatch/match and OS.
(B) Anti-HLA antibody negative group, HLA-DP loci mismatch/match and DFS.
(C) Anti-HLA antibody positive group, HLA-DP loci mismatch/match and
relapse.
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respectively (P ¼ .61). Moreover, there was a nonsigniﬁcant
trend towards lower OS (59.5% versus 80.8%, P ¼ .5754)
(Figure 3A) and DFS (59.6% versus 84.6%, P ¼ .3310)
(Figure 3B) in the 2 subgroups. No signiﬁcant differences
were found in relapse rate (P ¼ .8185).
In contrast, in the anti-HLA Abs-positive group, recipients
from donors with HLA-DP loci matches had a relapse rate
that was higher than that in recipients from donors with
HLA-DP loci mismatches (60.0% versus 27.4%, P ¼ .0951)
(Figure 3C). No signiﬁcant differences were found in aGVHD
(P ¼ .9307), OS (P ¼ .192), and DFS (P ¼ .2443).Multivariate Analysis
To further determine the effects of anti-HLA antibodies
before transplantation on the outcome of HSCT, a multivar-
iate analysis was performed. This analysis showed that pre-
existing anti-HLA antibodies was a risk factor for OS
(P ¼ .04; HR, 2.199; 95% CI, 1.037 to 4.661), aGVHD (P ¼ .03;
HR, 2.876; 95% CI, 1.106 to 7.475), and cGVHD (P ¼ .004; HR,
4.062; 95% CI, 1.580 to 10.440). In addition, advanced stage of
the disease at the time of transplantationwas a risk factor for
OS (P ¼ .026; HR, 2.391; 95% CI, 1.112 to 5.139) and DFS
(P ¼ .017; HR, 2.397; 95% CI, 1.172 to 4.903), and CD34þ cell
number (P ¼ .003; HR, 4.908; 95% CI, 1.743 to 13.824) and
ABO blood type (P ¼ .026; HR, 3.12; 95% CI, 1.153 to 8.444)
were risk factors for aGVHD (Table 4).
DISCUSSION
In this retrospective study, we have found that anti-HLA
antibodies and their dynamic changes negatively affect
outcomes of patients with hematologic malignancies un-
dergoing allo-HSCT from HLA-A, -B, -C, -DRB1, -DQB1, and
-DQA1 (12/12)ematched unrelated donors. Importantly, we
observed a higher incidence of aGVHD (grades II to IV) and
cGVHD in patients with anti-HLA antibodies, especially in the
antibodies persistently positive group. Furthermore, we
found that pre-existing anti-HLA antibodies were associated
with aGVHD and cGVHD in multivariate analysis. A recent
study of pediatric patients undergoing cord blood trans-
plantation also showed that anti-HLA antibodies are
responsible for higher GVHD [16]. It is interesting to note that
female patients and patients with a longer time frommonths
from diagnosis to transplantation (that is, above the median)
can produce antibodies, which is associated with higher
incidence of aGVHD. We speculate that anti-HLA antibodies
can participate in the humoral immunity and cellular im-
munity of the recipients by a direct binding or by an indirect
mechanism and play an important role in the GVHD process
for the cytokine inﬂammation. Therefore, we suggest that
routine inspection of anti-HLA antibodies and treatment
measures for sensitized patients of HSCT may be
indispensable.
An HLA-mismatched unrelated donor HSCT study indi-
cated that anti-HLA antibodies can be detected before and
may also appear after transplantation [17]. In the present
study, we detected a gradually declining rate of anti-HLA
antibodies at 1 month and 3 months after transplantation
compared with before transplantation, especially in patients
who were DSHAs positive before transplantation and were
converted to negative after transplantation. Pre-existing
anti-HLA antibodies may be related to a history of multiple
transfusions. Because anti-HLA antibodies can be maintained
for long time, we consider using plasma exchange, immu-
nosuppressors, and rituximab treatment program, especially
in patients with persistently positive antibodies. The treat-
ments for those patients should be appropriately prolonged
and the detection of anti-HLA antibodies should be pre-
formed frequently.
Some studies on allo-HSCT reported that the presence of
anti-HLA antibodies before transplantation is associated
with higher mortality and inferior OS and DFS [14,18-20].
However, the data for the association between the dynamic
changes of anti-HLA antibodies and outcomes are limited. In
this study, we found that patients with antibodies detected
before and after transplantation had inferior OS and DFSwith
a higher aGVHD rate than those without antibodies and the
role of antibodies is especially striking in AML/MDS patients.
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Z. Pan et al. / Biol Blood Marrow Transplant 22 (2016) 86e9594In addition, the dynamic changes of anti-HLA antibodies
during the 1 month after transplantation were associated
with higher TRM. Multivariate analysis also showed that
anti-HLA antibodies were a risk factor for survival. This is
important because it suggests that enhancing the intensity of
conditioning therapy and usingmonoclonal antibodies in the
therapeutic regimen may dampen the effect of anti-HLA
antibodies, thereby reducing mortality and improving the
outcomes.
It is well established that HLA-DPB1 disparities are asso-
ciated with a signiﬁcantly increased risk of GVHD and mor-
tality after HSCT from an unrelated donor compared with
after HSCT from identical HLA-DPB1 [12,21,22]. In this study,
we found that patients with HLA-DP allele or/and antigen
mismatch had a higher rate of GVHD, increased mortality,
and a lower rate of relapse. We speculate that HLA-DPB1
mismatches should be subdivided into permissive and
nonpermissive mismatches because they can induce allor-
eactive T cell responses [23,24] and cross-react with T cell
epitope [25,26]. Those results will be reported in future
studies.
In conclusion, our data suggest for the ﬁrst time to our
knowledge that dynamic changes of anti-HLA antibodies
before and after transplantation are an important index for
outcomes of HLA-12/12ematched unrelated donor HSCT.
Anti-HLA antibodies predicted for negative outcomes of
HSCT independent of HLA-DP loci mismatches. We want to
emphasize that a subset of patients with anti-HLA antibodies
before transplantation can turn to negative by the condi-
tioning regimen and immunosuppressive therapies. Patients
who continuously have anti-HLA antibodies should accept
more intensive therapeutic strategies with dynamic moni-
toring of anti-HLA antibodies.
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